Join

Compare · NVO vs RGNT

NVO vs RGNT

Side-by-side comparison of Novo Nordisk A/S (NVO) and Regentis Biomaterials Ltd. (RGNT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and RGNT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $215.95B, about 15686.2x RGNT ($13.8M).
  • RGNT has been more active in the news (14 items in the past 4 weeks vs 4 for NVO).
  • NVO has more recent analyst coverage (25 ratings vs 0 for RGNT).
MetricNVORGNT
Company
Novo Nordisk A/S
Regentis Biomaterials Ltd.
Price
-
-
Market cap
$215.95B
$13.8M
1M return
-
-
1Y return
-
-
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
AMEX
IPO
2025
News (4w)
4
14
Recent ratings
25
0
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Latest NVO

Latest RGNT